<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648933</url>
  </required_header>
  <id_info>
    <org_study_id>AOR10027</org_study_id>
    <nct_id>NCT01648933</nct_id>
  </id_info>
  <brief_title>Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis</brief_title>
  <acronym>PARCS</acronym>
  <official_title>Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at assessing diagnostic and therapeutic impact of Rubidium-82 PET in cardiac
      sarcoidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The presence of cardiac involvement is a serious complication of sarcoidosis. Early diagnosis
      is challenging since it relies on an array of clinical, biological and imaging abnormalities.
      Myocardial perfusion imaging with sestamibi is currently a major feature of the diagnosis,
      since it allows to evidence both microcirculatory impairments and scar. However, some
      technical limitations are inherent to SPECT, mainly poor spatial resolution and lack of
      attenuation correction, resulting in the absence of flow quantification. Rubidium-82 (Rb) PET
      proved to be more sensitive and specific than sestamibi SPECT in the diagnosis of coronary
      artery disease. Furthermore, it allows noninvasive measurement of coronary flow reserve.
      Finally, it exposes patients to lower radiation dose than SPECT. Therefore, Rb PET may help
      to better identify cardiac involvement of sarcoidosis, and hence to better select those
      patients who require high-dose steroids.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patient who has two different diagnostic and therapeutic attitude before knowing Rubidium-82 PET result and after knowing Rubidium-82 PET result</measure>
    <time_frame>60 days</time_frame>
    <description>to assess diagnostic and therapeutic impacts of myocardial perfusion analysis with Rubidium-82 PET in cardiac sarcoidosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of the cost for the use of Sestamibi SPECT and Rb-PET as MPI agents in cardiac sarcoidosis.</measure>
    <time_frame>9 months</time_frame>
    <description>to compare the cost between the two exams and the health-economic impact of Sestamibi SPECT and Rb-PET as MPI agents in cardiac sarcoidosis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Sarcoidosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rubidium PET:
Myocardial Perfusion Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Rubidium PET</intervention_name>
    <description>Myocardial Perfusion Imaging</description>
    <arm_group_label>Sarcoidosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) histologically proven sarcoidosis;

          -  (2) suspicion of cardiac involvement on symptoms, and/or ECG and/or echocardiogram.

        Exclusion Criteria:

          -  patient &lt; 18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Le Guludec, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier Bichat - Claude Bernard 46, rue Henri-Huchard</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2012</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sarcoidosis</keyword>
  <keyword>heart</keyword>
  <keyword>Rubidium</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

